Few shoppers have heard of Croda International (LSE:CRDA), yet many use its products daily. The Yorkshire-founded chemicals group makes speciality ingredients that other companies put into their own brands: the actives in an anti-ageing serum, the conditioning agents in a shampoo, the fragrance notes in a body wash. Croda sells the molecules; its customers sell the bottle.

The same scientific know-how also reaches the pharmacy. Croda Pharma says its adjuvants — the substances that help a Vaccine provoke a stronger immune response — feature in 15 of 24 vaccines listed by the World Health Organization, and it describes itself as the first supplier of lipids for a Covid-19 mRNA vaccine. Such lipids, an area in which its US Subsidiary Avanti Polar Lipids specialises, form the tiny fatty shells that carry genetic material into cells. A single chemistry toolkit therefore runs from the beauty counter to the clinic.

For investors, that link explains both the appeal and the recent pain: beauty is the growth engine, while the vaccine-related lipid Business has gone from Pandemic windfall to write-downs.

How the business makes money

Croda reports three divisions. Consumer Care is the largest, covering Beauty Actives, Beauty Care, Fragrances and Flavours, and Home Care. In the six months to 30 June 2026 it produced £523.7m of the group's £880.5m of sales and £98.1m of adjusted operating profit.

Life Sciences brings together Pharma, Crop Protection and Seed Enhancement, with first-half sales of £257.3m and adjusted operating profit of £53.7m. Pharma is split between Pharma Ingredients — excipients and consumer-health ingredients that make up roughly 70% of Pharma sales — and the more project-based Pharma Solutions, home to lipid delivery systems.

Industrial Specialties, the legacy division, made £99.5m of sales in the first half but only £4.0m of adjusted operating profit, a Margin of 4.1%.

Customers use Croda's ingredients in tiny quantities, so switching supplier means costly reformulation, which supports pricing. In the first half of 2026, price and mix added 3.4% to sales against Volume growth of 1.2%.

Recent performance

For the year to 31 December 2025, sales rose 4.4% to £1,699.4m, or 6.6% at constant currency. Adjusted pre-tax profit climbed 8.4% at constant currency to £276.2m and adjusted Earnings Per Share rose 2.5% to 146.2p. Reported pre-tax profit, however, fell 56.2% to £91.0m, reflecting £107.3m of impairments, £44.6m of costs linked to optimising lipid capacity and a £15.9m onerous contract provision. The full-year Dividend was lifted 0.9% to 111.0p.

First-quarter 2026 sales of £431m were up just 1% at constant currency, held back by an 8% fall in Crop Protection.

The half-year to 30 June 2026 was better. Sales rose 2.9% to £880.5m, or 4.6% organically. Adjusted pre-tax profit grew to £147.7m from £138.0m, the adjusted Operating Margin improved to 17.7% from 17.2%, and adjusted EPS rose 8.9% to 78.6p. Reported pre-tax profit rose to £107.4m from £85.5m. The Interim Dividend was held at 48.0p, and net Debt stood at £577.9m, or 1.4 times earnings before interest, tax, Depreciation and amortisation.

The divisional split was stark. Consumer Care grew 8.3% organically, led by a 19% jump in Beauty Actives, where ceramide sales rose 44%. Life Sciences was broadly flat, as Pharma Ingredients grew 7% but Pharma Solutions fell 17%, which management attributed to projects slipping into the second half.

Strategy and catalysts

Chief executive Steve Foots has set out a framework to 2028: Organic Sales growth of 3–6% a year from 2026 to 2028, an adjusted operating margin above 20% (from 17.4% in 2025), free Cash Flow above 12% of sales and a return on invested Capital above 10%. A transformation programme targets about £100m of annualised savings by 2028; £28m was delivered in 2025 and a further £18m in the first half of 2026. A working-capital drive aims to release around £50m.

Innovation is the other lever. New and protected products grew 6.9% organically in the first half. Croda launched KeraBio, a biotech-derived keratin ingredient for hair repair, and repositioned its Volufiline active for facial volume loss linked to GLP-1 weight-loss drugs. On 17 September 2026 it opened a global biotechnology centre at Sci-Tech Daresbury. In pharma, a June 2026 collaboration gives Avanti customers access to NovoArc's lipid technologies, which aim to make delivery more stable and potentially allow oral dosing of complex medicines.

Near-term catalysts include whether delayed Pharma Solutions projects land in the second half and whether Crop Protection's second-quarter recovery (up 5%) holds. The 2026 outlook was left unchanged in July.

Valuation talking points

At 3,289p on 22 September 2026, the shares trade on about 22.5 times 2025 adjusted EPS of 146.2p, with a historic Dividend Yield of about 3.4%.

Dividend cover is thin. Croda's policy is to pay out 40–50% of adjusted earnings, yet the 2025 dividend absorbed roughly three-quarters of adjusted EPS, which is why the interim payment was frozen "to restore earnings cover". Leverage of 1.4 times sits within the 1–2 times target range, and no buyback has been announced.

The bull case

  • Beauty Actives is growing fast, with first-half organic growth of 19% and new products such as ceramides gaining traction.
  • Self-help savings of around £100m by 2028 give margin upside that management says does not depend on a market recovery.
  • Deep formulation relationships and pricing power have allowed price and mix to outpace volume.
  • Adjuvant and lipid expertise keep Croda positioned for future vaccine and nucleic-acid medicines.

The bear case

  • The lipid business has swung from boom to write-downs, and Pharma Solutions Revenue remains lumpy and hard to forecast.
  • Large 2025 impairments raise questions about returns on past investment.
  • Dividend cover is well below policy, capping near-term payout growth.
  • Crop Protection and North America have been volatile, and currency movements affect reported profit.
  • Industrial Specialties earns low margins and is expected to shrink or grow only modestly.

The bottom line

Croda's story is a tale of two customer groups built on one chemistry base. Skincare and fragrance Demand is currently doing the heavy lifting, while the vaccine-linked lipid operation is being right-sized after the pandemic surge faded. First-half figures suggest adjusted earnings are recovering, and the cost programme offers a route to better margins.

The central question is execution: whether Croda can reach its 20%-plus margin goal by 2028 and rebuild dividend cover while keeping innovation flowing. With the shares on a premium multiple, the market is already pricing in a good deal of that progress.